BioStem Technologies, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $46.1M
- Price
- $2.47
- % Change (Daily % change from the live per-ticker quote feed.)
- -10.34%
- Volume
- 128.6K
About
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
Quick stats
Shares outstanding18.7M
Computed float14.2M
Float / shares76.0%
Cash runway (months)1.5
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001658678
AI Summary
AI-generated1/29
minorbullishother
BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio
BioStem Technologies announced the USPTO issued one new patent and three notices of allowance, with Mexico's IMPI issuing one additional notice of allowance, across its placental and umbilical cord tissue technologies.
The patents cover sterile human placental allografts for wounds and diabetic foot ulcers, micronized umbilical cord compositions for wound healing, and umbilical cord extracts for joint cushioning and inflammation treatment.
The company's IP portfolio now includes more than 100 patents and applications worldwide, supporting its wound care, surgical and joint allograft products.
Red flags
- forward-looking statements note Nasdaq continued-listing compliance and financing risks